Embedded Files
Clinical Director, Breast Oncology Program
Stuart B. Padnos Professor in Breast Cancer
Principal Investigator
Dr. Daniel F. Hayes, MD - Curriculum Vitae
Daniel Fleming Hayes, M.D. is the Stuart B. Padnos Professor of Breast Cancer Research at the University of Michigan Rogel Cancer Center and Professor of Internal Medicine, Division of Hematology Oncology at the University of Michigan School of Medicine.
Over the last two decades, Dr. Hayes’ professional training and career have been directed toward bridging the gap between laboratory and clinical research. He received a bachelor’s degree (1974) in biology and a master’s degree (1977) in biochemistry and an M.D. (1979) at Indiana University. He completed his residency in internal medicine at the University of Texas Health Science Center at Dallas, Texas (Parkland Memorial and affiliated hospitals) and a fellowship in medical oncology from 1982–1985 at Harvard’s Dana Farber Cancer Institute in Boston, He then joined the faculty at DFCI and served as the Medical Director of the Breast Evaluation Center from 1992-1996, when he moved to Georgetown University where he led the breast cancer group until 2001. From then until 2017, he was the co-Director of the Breast Oncology Program at the University of Michigan Comprehensive Cancer Center.
Dr. Hayes’ research has focused on translational breast cancer research, in particular directed towards investigations of tumor biomarkers in the germline, cancer tissue, and circulation. He co-chaired the Consortium on Breast Cancer Pharmacogenomics (COBRA) to study inherited germline mutations that might guide anti-estrogen therapies, and he has led studies in the cooperative groups to determine if various biomarkers in breast cancer tissue, such as HER2 and the 21-gene Recurrence Score (OncotypeDx) can be used to direct the use of adjuvant chemotherapy. Dr. Hayes published the initial studies of the circulating MUC-1 antigen (known as the CA15-3 assay), now widely used to monitor patients with metastatic breast cancer, and he has also led ground-breaking pre-clinical and clinical trials of circulating tumor cells (CTC). in metastatic breast cancer.
Dr. Hayes has also published extensively regarding establishment of guidelines for the use of tumor biomarker tests in clinical practice, and he was a member, and has served as chair, of several tumor biomarker guidelines panels convened by the American Society of Clinical Oncology (ASCO) and the College of American Pathologists (CAP). He is widely considered to be an expert in the field of clinical research of breast cancer, especially with new hormonal and chemotherapeutic treatments. He lectures and publishes extensively regarding the management of patients with breast cancer. In 2007, his accomplishments in translational research and mentoring were highlighted when he was named recipient of the inaugural Gianni Bonnadonna Breast Cancer Award by the American Society of Clinical Oncology (ASCO).
Dr. Hayes is a past Chair of the Solid Tumor Correlative Sciences Committee of the Cancer and Leukemia Group B (CALGB), the Breast Cancer Translational Medicine Committee of the Southwest Oncology Group (SWOG), and the Correlative Sciences Committee of the North American Breast Cancer Intergroup. He co-chairs the Trans-Ox Committee, which oversees translational studies in the Early Breast Cancer Trialists’ Collaborative Group of Oxford. Dr. Hayes served on the ASCO Board of Directors and from 2015–2018 he was President of ASCO. He is a Komen Scholar, and he is or has been on several editorial boards of leading cancer journals. He has published more than 200 peer-reviewed papers, 150 book chapters, reviews, and editorials, and he has edited or co-edited five textbooks on general oncology, breast cancer and tumor markers.
Andi Cani, PhD
Research Investigator
Contact: acani@med.umich.edu
Dr. Andi Cani was born and raised in Albania and received his BS and MS in Biochemistry and Molecular Biology at Wayne State University in Detroit, MI. He completed his PhD at the University of Michigan Medical School, Pathology Department and Rogel Cancer Center under Drs. Scott Tomlins and Arul Chinnaiyan. His thesis work centered on prostate cancer precision oncology and diagnostics using next-generation technologies including DNA and RNA sequencing.
Dr. Cani joined the group of Dr. Daniel F. Hayes as a Post-doctoral Research Fellow in January 2020 in the Hematology/Oncology Division of the Internal Medicine Department and the Rogel Cancer Center, University of Michigan (Michigan Medicine). His current work focuses on genomic profiling of circulating tumor cells in metastatic breast cancer patients to discover cancer molecular mechanisms at single cell resolution in relation to clinical trial outcomes. His work also entails elucidating circulating tumor cell cluster genomics and biology.
Associate Research Scientist, Pathology
Research Assistant Professor of Biostatistics
Kelley joined the University of Michigan after she earned her doctoral degree in Biostatistics from the University of Pittsburgh Graduate School of Public Health in 2012. Kelley worked at the National Surgical Adjuvant Breast and Bowel Project (NSABP) from 2008-2012 under Dr. Joseph Costantino. Her research centers on survival analysis, adaptive treatment strategies, clinical trial design and analysis with applications to cancer research, specifically, breast cancer.
Assistant Professor, Biostatistics
Emily Dolce, BS
Research Lab Technician Lead/Lab Manager
Danyah Alomari, BS
Research Lab Technician Associate
Former Lab Members:
Costanza Paoletti, MD
Research Investigator
Dr. Costanza Paoletti received her M.D. from the University of Florence (Italy) in 2004, and her clinical training in Medical Oncology with honors in November 2008 in Florence, Italy. From February to October 2008, she trained at the H. Lee Moffitt Cancer Center and Research Institute in Tampa, Florida, focusing on cancer treatment in the elderly under the direction of Dr. Lodovico Balducci. On her return to Italy in January 2009, she joined the “Sandro Pitigliani” Medical Oncology Unit, Hospital of Prato, led by Dr. Angelo Di Leo, a leading breast oncologist in Europe.
In January 2010, Dr. Paoletti served as a Post-doctoral Research Fellow in the laboratory of Dr. Daniel F. Hayes within the Breast Oncology Program at the University of Michigan Rogel Cancer Center (UM RCC). During this time, her focus included pre-clinical and pilot clinical studies of the utility of monitoring circulating tumor cells (CTC) number and phenotype. She designed a North American multi-institutional trial (COMETI Phase 2), that opened in spring of 2013 and for which she is the national study chair.
In January 2014, she began her appointment as Research Investigator at the UM RCC where she continues to focus on CTC enumeration and characterization as well as new drug development and co-development of biomarkers. She is currently planning moderate studies using CTCs as pharmacodynamic tools to monitor the effects of targeted treatments.
Nahomi Tokudome, MD
Research Fellow
Dr. Tokudome is a general surgeon and medical oncologist specializing in breast cancer treatment from Kagoshima, Japan. Her research interests included circulating tumor cell (CTC) detection, isolation, and capture. Specifically, her research involved developing new technology for separating and capturing circulating tumor cells from blood in real time without relying on antibodies, magnetic particles or fixation techniques. This process leaves the cells alive for further testing. She was involved in designing clinical trials using the assay based on this novel device.
Technicians:
Kimberly Aung
Maria Muniz
LeAnn McNutt
Paul Baratta
Elizabeth Darga
Alissa Turnbull
Marty Brown
Research Laboratory Specialist Senior
Marty Brown is the lab manager for the Hayes Lab and Breast Oncology Tissue Bank. Her work involves recording, processing, storing, and distributing clinical lab samples collected from patients enrolled in breast cancer clinical research studies at the Rogel Cancer Center.
She also is involved in producing xenografts from tumor and fluids collected from patients enrolled in breast cancer clinical research studies at the University of Michigan. The process involves preparing human samples for injection and subsequent growth in the mouse mammary fat pad.
Page updated
Report abuse